OQROGet OQRO Pro
Insider trade

Cytokinetics (CYTK)Officer sold ~$875K

Andrew Callos, Officer at Cytokinetics, sold ~$875K of Cytokinetics shares.

~$875K
Approx. value · 11K sh @ $77.25
59K
Holds after · shares reported
Traded
May 5, 2026
Filed
May 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 9, 2026Insider · 3 peopleInsiders: 3 sales (~$815K)
  2. Mar 16, 2026InsiderOfficer sold ~$104K of CYTK shares in the open market
  3. Mar 17, 2026Insider · 4 peopleInsiders: 7 sales (~$3.9M)
  4. Mar 18, 2026InsiderOfficer sold ~$120K of CYTK shares in the open market
  5. Mar 31, 2026InsiderOfficer sold ~$237K of CYTK shares in the open market
  6. Apr 1, 2026InsiderCEO sold ~$500K of CYTK shares in the open market
  7. Apr 7, 2026Insider · 1 personInsiders: 2 sales (~$293K)
  8. Apr 15, 2026Insider · 2 peopleInsiders: 2 sales (~$982K)
  9. Apr 21, 2026InsiderOfficer sold ~$230K of CYTK shares in the open market
  10. Apr 29, 2026InsiderCEO sold ~$447K of CYTK shares in the open market
  11. Apr 30, 2026InsiderOfficer sold ~$949K of CYTK shares in the open market
  12. May 1, 2026InsiderOfficer sold ~$1.03M of CYTK shares in the open market
  13. May 5, 2026 · this disclosureInsiderOfficer sold ~$875K of CYTK shares in the open market

What came next

  1. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  2. May 5, 2026Insider · 4 peopleInsiders: 4 sales (~$3.9M)
  3. May 14, 2026InsiderCEO sold ~$584K of CYTK shares in the open market
  4. May 19, 2026InsiderOfficer sold ~$265K of CYTK shares in the open market
  5. May 27, 2026InsiderCEO sold ~$579K of CYTK shares in the open market
  6. Jun 1, 2026Insider · 3 peopleInsiders: 3 sales (~$1.7M)
  7. Jun 9, 2026InsiderOfficer sold ~$238K of CYTK shares in the open market
  8. Jun 15, 2026InsiderCEO sold ~$528K of CYTK shares in the open market
  9. Jun 23, 2026InsiderOfficer sold ~$278K of CYTK shares in the open market
  10. Jun 24, 2026InsiderCFO sold ~$3.19M of CYTK shares in the open market
  11. Jun 29, 2026InsiderCFO sold ~$266K of CYTK shares in the open market
  12. Jun 30, 2026CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
  13. Jul 1, 2026Insider · 3 peopleInsiders: 3 sales (~$2.0M)
  14. Jul 7, 2026InsiderOfficer sold ~$303K of CYTK shares in the open market
  15. Jul 13, 2026Insider · 1 personInsiders: 2 sales (~$615K)
  16. Jul 21, 2026InsiderOfficer sold ~$282K of CYTK shares in the open market
  17. Jul 27, 2026InsiderCEO sold ~$607K of CYTK shares in the open market
  18. Jul 30, 2026InsiderOfficer sold ~$1.12M of CYTK shares in the open market
  19. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results
  20. Aug 10, 2026InsiderCEO sold ~$576K of CYTK shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cytokinetics

For Cytokinetics, OQRO holds 18 insider filings (SEC Form 4 or Form 144) and 11 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.

Other recent filings by Andrew Callos, EVP, Chief Commercial Officer

The full history of Andrew Callos, EVP, Chief Commercial Officer is on the profile page.

How this filing works

Other disclosures at Cytokinetics

Everything OQRO holds on this company is on its CYTK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data